Skip to main content
CG Invites Co., Ltd. logo

CG Invites Co., Ltd. — Investor Relations & Filings

Ticker · 083790 ISIN · KR7083790006 KO Manufacturing
Open in API
Filings indexed 450 across all filing types
Latest filing 2026-05-18 Director's Dealing
Country KR South Korea
Listing KO 083790

About CG Invites Co., Ltd.

https://cginvites.com/en

CG Invites Co., Ltd. is a biopharmaceutical company specializing in digital genomics and personalized medicine. The company's activities are focused on four main areas: genomics, personalized cancer vaccines, digital therapeutics, and the development of chemical and biological drugs. It utilizes Whole Genome Sequencing to support precision medicine initiatives and develops mRNA-based personalized cancer vaccines. The company also creates software-based medical interventions, known as digital therapeutics. Its drug development pipeline includes therapeutics for oncology and inflammatory diseases, such as Acelex for osteoarthritis, Ivaltinostat for pancreatic cancer, and Camrelizumab for immuno-oncology. The company's research approach is based on structural chemoproteomics and the integration of genomic data to develop targeted treatments.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is a Korean insider ownership report (“임원ㆍ주요주주 특정증권등 소유상황보고서”) detailing an executive’s shareholdings and changes (acquisitions/dispositions) in the company’s stock. It constitutes a report of personal share transactions by a company director (insider trading disclosure). Therefore it matches the Director's Dealing category.
2026-05-18 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” covering the period January 1 to March 31, 2026 (first quarter) for a listed company. It includes detailed financial tables, business overview, capital changes, board changes, and substantive financial data typical of a quarterly interim report. Therefore, it is classified as an Interim / Quarterly Report (IR). Q1 2026
2026-05-14 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 75% confidence The document is a brief announcement setting the record date (shareholder register closure period) for an upcoming general meeting. It does not present actual financial statements or vote results, nor does it announce dividends, share capital changes, or detailed governance rules. It is a routine regulatory notice in the company’s local filings. Therefore it best fits the fallback “Regulatory Filings” category (RNS).
2026-05-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is a regulatory form reporting the share ownership and transaction details of an executive/major shareholder (“임원ㆍ주요주주 특정증권등 소유상황보고서”), listing the number of shares held and changes through on‐market purchases. This is a classic insider holdings and transactions disclosure rather than an announcement of broader corporate financial results or governance materials. Therefore, it fits the Director’s Dealing category.
2026-05-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 98% confidence The document is titled “임원·주요주주 특정증권등 소유상황보고서” submitted to the Korea Financial Services Commission and Korea Exchange. It details officers’ and major shareholders’ holdings and on-market share purchase transactions, including dates, quantities, and ownership ratios. This corresponds to an insider trading/insider share transactions report by directors or major shareholders. Therefore, it falls under Director’s Dealing (DIRS).
2026-05-13 Korean
단일판매ㆍ공급계약해지
Regulatory Filings
2026-04-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.